Potassium Citrate

For the symptomatic relief of dysuria associated with mild urinary tract infections, especially cystitis.

Indications stated on label:

For the relief of the symptoms of cystitis and other mild urinary tract infections.

1)]. 2)] . 3)].

Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

AND CLINICAL USE UROCIT®-K (Potassium Citrate Extended-Release Tablets, USP) is indicated for the management or renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.

CONTRAINDICATIONS UROCIT®-K (Potassium Citrate Extended-Release Tablets, USP) is contraindicated in: 1. , because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. 2. Patients with active urinary tract infection (with urea-splitting or other organisms, in association with either calcium or struvite stones).

The ability of UROCIT®-K to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from UROCIT®-K therapy might promote further bacterial growth. 3. Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest.